Patients and physicians came together in this international project to agree on what is critical to be measured in psoriatic arthritis clinical trials. This project was critical in defining what outcomes are important for both patients and their doctors.
The authors found that just very few patients reach durable remission, regardless of defining remission on-treatment or off-treatment. The higher the patients’ disease activity and treatment was when they entered our analysis, the lower was their chance of achieving remission.
Our study was to evaluate changes in transaminase levels (AST/ALT) over one week after methotrexate was given to rheumatoid arthritis patients. We evaluated 13 patients with RA taking stable doses of methotrexate, and then sequential blood samples were obtained over the course of 7 days.
In our manuscript entitled “Unique Abnormalities in Right Ventricular Longitudinal Strain in Systemic Sclerosis Patients”, we utilized novel echocardiographic techniques for the detection of right ventricular abnormalities in a large cohort of systemic sclerosis patients.
New cancer therapies that work by activating the immune system can induce side effects. We described the largest series of patients with inflammatory arthritis and sicca syndrome (severe dry eyes and dry mouth) from these therapies.
Scleroderma patients with autoantibodies against centromere proteins and/or IFI16 have a higher risk of severe vascular complications. In this study, we show that expression of these autoantigens is enriched in vascular progenitors and mature endothelial cells.
